Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer

od Roberts, Kate E, Rickett, Kirsty, Vagenas, Dimitrios, Woodward, Natasha E
Izdano u Cochrane Database Syst Rev (2018)

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer

od Roberts, Kate E, Rickett, Kirsty, Chatfield, Mark D, Woodward, Natasha E
Izdano u Cochrane Database Syst Rev (2018)

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer

od Roberts, Kate E, Rickett, Kirsty, Feng, Sophie, Vagenas, Dimitrios, Woodward, Natasha E
Izdano u Cochrane Database Syst Rev (2020)

Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report

od Moloney, Thomas P, Xu, Wen, Rallah-Baker, Kristopher, Oliveira, Niara, Woodward, Natasha, Farrah, Jonathon J
Izdano 2014

Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b

od Snell, Cameron E., Gough, Madeline, Liu, Cheng, Middleton, Kathryn, Pyke, Christopher, Shannon, Catherine, Woodward, Natasha, Hickey, Theresa E., Armes, Jane E., Tilley, Wayne D.
Izdano u Br J Cancer (2018)

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy

od Rugo, Hope S, Ettl, Johannes, Hurvitz, Sara A, Gonçalves, Anthony, Lee, Kyung-Hun, Fehrenbacher, Louis, Mina, Lida A, Diab, Sami, Woodward, Natasha E, Yerushalmi, Rinat, Goodwin, Annabel, Blum, Joanne L, Martin, Miguel, Quek, Ruben G W, Tudor, Iulia Cristina, Bhattacharyya, Helen, Gauthier, Eric, Litton, Jennifer K, Eiermann, Wolfgang
Izdano u JNCI Cancer Spectr (2019)